针对降钙素基因相关肽（CGRP）或其受体的治疗性抗体。
Therapeutic antibodies against CGRP or its receptor.
作者信息
Bigal Marcelo E, Walter Sarah, Rapoport Alan M
机构信息
Vice President, Migraine & Headache Clinical Development, Teva Pharmaceuticals, Frazer, PA.
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY.
出版信息
Br J Clin Pharmacol. 2015 Jun;79(6):886-95. doi: 10.1111/bcp.12591.
Abstract
CGRP is an extensively studied neuropeptide that has been implicated in the pathophysiology of migraine. While a number of small molecule antagonists against the CGRP receptor have demonstrated that targeting this pathway is a valid and effective way of treating migraine, off-target hepatoxicity and formulation issues have hampered the development for regulatory approval of any therapeutic in this class. The development of monoclonal antibodies to CGRP or its receptor as therapeutic agents has allowed this pathway to be re-investigated. Herein we review why CGRP is an ideal target for the prevention of migraine and describe four monoclonal antibodies against either CGRP or its receptor that are in clinical development for the treatment of both episodic and chronic migraine. We describe what has been publically disclosed about their clinical trials and future clinical development plans.
摘要
降钙素基因相关肽（CGRP）是一种经过广泛研究的神经肽，它与偏头痛的病理生理学有关。虽然一些针对CGRP受体的小分子拮抗剂已证明，靶向该途径是治疗偏头痛的一种有效方法，但脱靶肝毒性和制剂问题阻碍了该类任何治疗药物获得监管批准的进程。开发针对CGRP或其受体的单克隆抗体作为治疗药物，使得这一途径能够重新得到研究。在此，我们综述了为什么CGRP是预防偏头痛的理想靶点，并描述了四种针对CGRP或其受体的单克隆抗体，它们正处于治疗发作性和慢性偏头痛的临床开发阶段。我们介绍了关于其临床试验和未来临床开发计划已公开披露的信息。
相似文献
1
Therapeutic antibodies against CGRP or its receptor.针对降钙素基因相关肽（CGRP）或其受体的治疗性抗体。
Br J Clin Pharmacol. 2015 Jun;79(6):886-95. doi: 10.1111/bcp.12591.
2
Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.降钙素基因相关肽 (CGRP) 与偏头痛：当前认识和研发状况。
Headache. 2013 Sep;53(8):1230-44. doi: 10.1111/head.12179. Epub 2013 Jul 12.
3
Patent watch: Migraine therapies targeting the CGRP pathway: intellectual property landscape.专利观察：针对降钙素基因相关肽（CGRP）通路的偏头痛疗法：知识产权格局
Nat Rev Drug Discov. 2016 Jan;15(1):8-9. doi: 10.1038/nrd.2015.11. Epub 2015 Dec 16.
4
CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.降钙素基因相关肽与偏头痛：阻断降钙素基因相关肽配体和受体在偏头痛治疗中的作用。
Drugs. 2018 Jun;78(9):913-928. doi: 10.1007/s40265-018-0923-5.
5
Calcitonin gene-related peptide (CGRP): a new target for migraine.降钙素基因相关肽（CGRP）：偏头痛的新靶点。
Annu Rev Pharmacol Toxicol. 2015;55:533-52. doi: 10.1146/annurev-pharmtox-010814-124701. Epub 2014 Oct 8.
6
Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.聚焦偏头痛的抗 CGRP 单克隆抗体：迄今为止的临床证据。
Clin Pharmacol Drug Dev. 2017 Nov;6(6):534-547. doi: 10.1002/cpdd.345. Epub 2017 Apr 14.
7
Antigens and Antibodies in Disease With Specifics About CGRP Immunology.疾病中的抗原和抗体——CGRP 免疫学详解。
Headache. 2018 Nov;58 Suppl 3:230-237. doi: 10.1111/head.13409. Epub 2018 Sep 5.
8
CGRP as the target of new migraine therapies - successful translation from bench to clinic.降钙素基因相关肽（CGRP）作为新型偏头痛治疗靶点——从实验室到临床的成功转化。
Nat Rev Neurol. 2018 Jun;14(6):338-350. doi: 10.1038/s41582-018-0003-1.
9
Targeting calcitonin gene-related peptide: a new era in migraine therapy.针对降钙素基因相关肽：偏头痛治疗的新时代。
Lancet. 2019 Nov 9;394(10210):1765-1774. doi: 10.1016/S0140-6736(19)32504-8. Epub 2019 Oct 23.
10
CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.降钙素基因相关肽单克隆抗体治疗偏头痛：作用机制和研究进展。
BioDrugs. 2017 Dec;31(6):487-501. doi: 10.1007/s40259-017-0250-5.
引用本文的文献
1
Additional effect of erenumab for patients with chronic migraine treated with onabotulinumtoxin A-real-world data from a preliminary cohort study.erenumab对接受A型肉毒毒素治疗的慢性偏头痛患者的附加效应——一项初步队列研究的真实世界数据
Front Neurol. 2024 Jun 26;15:1370503. doi: 10.3389/fneur.2024.1370503. eCollection 2024.
2
Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults.艾普替奈umab-jjmr，一种针对降钙素基因相关肽的人源化单克隆抗体，用于成人偏头痛的预防性治疗。
Health Psychol Res. 2022 Nov 12;10(5):38439. doi: 10.52965/001c.38439. eCollection 2022.
3
Rimegepant for the treatment of migraine.利美尼定用于偏头痛治疗。
Health Psychol Res. 2022 Oct 12;10(5):38534. doi: 10.52965/001c.38534. eCollection 2022.
4
New Approaches to Shifting the Migraine Treatment Paradigm.转变偏头痛治疗模式的新方法。
Front Pain Res (Lausanne). 2022 Sep 6;3:873179. doi: 10.3389/fpain.2022.873179. eCollection 2022.
5
Observations from a prospective small cohort study suggest that CGRP genes contribute to acute posttraumatic headache burden after concussion.一项前瞻性小型队列研究的观察结果表明，降钙素基因相关肽（CGRP）基因在脑震荡后急性创伤后头痛负担中起作用。
Front Neurol. 2022 Aug 5;13:947524. doi: 10.3389/fneur.2022.947524. eCollection 2022.
6
Headache as a Neurologic Manifestation of Systemic Disease.头痛作为全身性疾病的神经系统表现
Curr Treat Options Neurol. 2022;24(1):17-40. doi: 10.1007/s11940-022-00704-9. Epub 2022 Mar 18.
7
Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives.慢性偏头痛的病理生理学与治疗：当前观点综述
Front Pain Res (Lausanne). 2021 Aug 25;2:705276. doi: 10.3389/fpain.2021.705276. eCollection 2021.
8
The Vascular-Dependent and -Independent Actions of Calcitonin Gene-Related Peptide in Cardiovascular Disease.降钙素基因相关肽在心血管疾病中的血管依赖性和非依赖性作用
Front Physiol. 2022 Feb 25;13:833645. doi: 10.3389/fphys.2022.833645. eCollection 2022.
9
The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions.加卡尼单抗在偏头痛预防中的作用：现有数据与未来方向
Pharmaceuticals (Basel). 2021 Mar 9;14(3):245. doi: 10.3390/ph14030245.
10
Cluster headache pathophysiology - insights from current and emerging treatments.丛集性头痛的病理生理学——当前和新兴治疗方法的启示。
Nat Rev Neurol. 2021 May;17(5):308-324. doi: 10.1038/s41582-021-00477-w. Epub 2021 Mar 29.
本文引用的文献
1
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.促甲状腺素相关肽抗体 ALD403 预防频发阵发性偏头痛的安全性和有效性：一项随机、双盲、安慰剂对照、探索性 2 期临床试验。
Lancet Neurol. 2014 Nov;13(11):1100-1107. doi: 10.1016/S1474-4422(14)70209-1. Epub 2014 Oct 5.
2
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.LY2951742 用于预防偏头痛的安全性和疗效：一项 2 期、随机、双盲、安慰剂对照研究。LY2951742 是一种降钙素基因相关肽的单克隆抗体。
Lancet Neurol. 2014 Sep;13(9):885-92. doi: 10.1016/S1474-4422(14)70128-0. Epub 2014 Aug 10.
3
Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide.静脉注射抗降钙素基因相关肽单克隆抗体LBR-101后食蟹猴心血管参数的评估
MAbs. 2014 Jul-Aug;6(4):871-8. doi: 10.4161/mabs.29242. Epub 2014 May 21.
4
Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP.使用抗降钙素基因相关肽单克隆抗体LBR-101长期抑制降钙素基因相关肽后女性的心血管和血流动力学参数。
Cephalalgia. 2014 Oct;34(12):968-76. doi: 10.1177/0333102414527646. Epub 2014 Mar 24.
5
Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.偏头痛的单克隆抗体：抑制降钙素基因相关肽活性。
CNS Drugs. 2014 May;28(5):389-99. doi: 10.1007/s40263-014-0156-4.
6
Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program.LBR-101（一种可阻断降钙素基因相关肽与其受体结合的人源化单克隆抗体）的安全性和耐受性：1期试验项目结果
Cephalalgia. 2014 Jun;34(7):483-92. doi: 10.1177/0333102413517775. Epub 2013 Dec 23.
7
Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system.外周三叉血管系统中储存 CGRP 和 CGRP 受体的神经纤维的分化。
J Pain. 2013 Nov;14(11):1289-303. doi: 10.1016/j.jpain.2013.03.010. Epub 2013 Aug 17.
8
Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.降钙素基因相关肽 (CGRP) 与偏头痛：当前认识和研发状况。
Headache. 2013 Sep;53(8):1230-44. doi: 10.1111/head.12179. Epub 2013 Jul 12.
9
Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).发作性偏头痛和慢性偏头痛预防性药物的使用模式和停药原因：来自第二次国际偏头痛负担研究（IBMS-II）的结果。
Headache. 2013 Apr;53(4):644-55. doi: 10.1111/head.12055. Epub 2013 Mar 4.
10
Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards subcommittee of the American Academy of Neurology and the American Headache Society.基于证据的指南更新：成人发作性偏头痛预防的药物治疗：美国神经病学学会和美国头痛学会质量标准小组委员会的报告。
Neurology. 2013 Feb 26;80(9):869-70. doi: 10.1212/01.wnl.0000427909.23467.39.
Zotero 插件